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Abstract
Background: Treatment of neuronal PC12 cells with ATP induces depolarisation and increases intracellular calcium
levels via purinergic receptors. In many cell types, sustained elevation of intracellular calcium levels cause changes
in gene expression via activation of the transcription factor NFAT (nuclear factor of activated T cells). We have
therefore characterised the signalling pathway by which ATP regulates NFAT-dependent gene expression in PC12
cells.
Results: The activation of NFAT transcriptional activity by extracellular ATP was characterised with the help of
reporter gene assays. Treatment of PC12 cells with ATP elicited a dose-dependent increase in luciferase activity
(EC50 = 78 μM). UTP, 4-benzoylbenzoyl ATP and a,b-methylene ATP did not mimic the effect of ATP, which was
abolished by treatment with the P2X receptor antagonist pyridoxal-phosphate-6-azophenyl-2’,4’-disulfonate
(PPADS). This pharmacological characterisation provides evidence for a critical role of ionotropic P2X receptors.
Blockade of L-type voltage-dependent calcium channels by nifedipine reduced the response of NFAT to ATP,
indicating that a depolarisation-mediated calcium influx was required for maximal NFAT activation. Inhibition of
store-operated calcium entry by the pyrazole derivative BTP2 also diminished ATP-dependent NFAT activation.
Furthermore, ATP-induced NFAT activation was associated with the activation of the mitogen-activated protein
kinases ERK1/2. Finally, treatment with ATP increased the levels of the NFAT target transcripts, RCAN1-4 (regulator
of calcineurin) and BDNF (brain derived neurotrophic factor).
Conclusion: The present data show that ATP induces NFAT-dependent changes in gene expression in PC12 cells
by acting on P2X receptors. Maximal NFAT activation depends on both depolarisation-induced calcium influx and
store-operated calcium entry and requires the activity of the protein phosphatase calcineurin and the mitogen-
activated protein kinase cascade.
Background
Purinergic signalling plays a significant role in neuro-
transmission and neuromodulation in many regions of
the brain as well as in the spinal cord and peripheral
neurons [1,2]. Among purinergic agonists, extracellular
ATP is a potent signalling molecule abundantly present
in the central nervous system. ATP is secreted from
many neurons as a cotransmitter by vesicular exocytotic
release, but also leaks from injured or dying cells [3]. In
addition, many cell types, including glial cells, can also
release ATP in response to stimuli such as hypoxia or
certain agonists independently of cell damage and
thereby modulate the function of adjacent neurons.
Once released into the extracellular space, ATP acts
on specific receptors that belong to two main subclasses:
ligand-gated P2X cation-selective channels and G pro-
tein-coupled P2Y receptors [4]. Both receptor classes
evoke calcium responses. P2X receptors can induce
depolarisation-induced calcium entry and are permeable
to Ca2+, whereas most P2Y receptors couple to phos-
pholipase Cb isoforms, which leads to the release of Ca2
+ from internal stores. Purinergic effects mediated by
Ca2+ signalling include presynaptic neurotransmitter
release, hormone secretion, calcium wave propagation
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between astrocytes and activation of primary nociceptive
neurons [3,5-7].
Although purinergic receptors are abundant in the
nervous system and have been extensively characterised
with respect to their short-term effects on neuronal
function, less is known about the long-term effects of
their activation in neurons. There is evidence that extra-
cellular nucleotides affect neuronal differentiation and
survival, but the signalling pathways that mediate these
effects are largely unexplored [8]. Specifically, the
increase in intracellular Ca2+ concentrations after activa-
tion of purinergic receptors is expected to influence
gene expression. The calcineurin-NFAT (nuclear factor
of activated T-cells) pathway is a major mediator of Ca2
+ effects on gene expression in neuronal cells and plays
a key role in neuronal development and function [9-11].
Surprisingly, the effects of purinergic receptors on
NFAT signalling and NFAT-dependent gene expression
have not yet been studied in neuronal cells.
The rat pheochromocytoma cell line PC12 is a well-
characterised model system for purinergic effects. PC12
cells express P2X and P2Y receptors and show increases
in intracellular Ca2+ concentration upon stimulation
with extracellular ATP [12-16]. Extracellular ATP stimu-
lates catecholamine release from PC12 cells, enhances
their sensitivity to nerve growth factor, promotes neurite
outgrowth and regulates cytoskeleton remodelling
[13,15,17,18]. Moreover, PC12 cells express the compo-
nents of the calcineurin-NFAT pathway and have been
used to characterise NFAT-dependent changes in gene
expression [19-21].
Here we have tested the hypothesis that extracellular
ATP can modulate gene expression in neuronal cells via
the calcineurin-NFAT pathway. We show that ATP sti-
mulates NFAT transcriptional activity through the acti-
vation of P2X receptors, causes the activation of ERK1/2
kinases and induces the expression of an NFAT target
gene in PC12 cells. These results suggest that extracellu-
lar ATP can act on neuronal cells by inducing NFAT-
dependent changes in gene expression.
Results
Extracellular ATP induces NFAT-dependent reporter gene
activity in PC12 cells
To study the effect of extracellular ATP on the activa-
tion of NFAT in neuronal cells, we generated a stable
PC12 subclone expressing luciferase under the control
of a NFAT-driven promoter (PC12-NFAT-Luc). Treat-
ment of PC12-NFAT-Luc cells with ATP strongly
induced luciferase activity, with a maximal response at
300 μM ATP (58 ± 12-fold increase, mean and S.D. of 3
independent experiments) (Figure 1). Significant stimu-
lation of NFAT activation was detected at a concentra-
tion as low as 1 μM ATP (2.93 ± 0.23-fold induction,
mean ± S.D.). The half-maximal effect was produced at
a concentration of EC50 = 78 μM ATP. It is important
to note that the actual concentration of ATP is not con-
stant during the incubation time of 3 h because PC12
cells express multiple ecto-ATPases [22]. Under the
conditions of this experiment, the half life of ATP was
~ 40 min (data not shown). No obvious toxicity was
observed in the trypan blue uptake test after treatment
of the cells with 300 μM ATP for 3 h.
Pharmacological characterisation of purinergic receptors
that mediate NFAT activation in PC12 cells
We aimed to characterise the purinergic receptor
responsible for the stimulatory effect of ATP on NFAT
with different agonists and antagonists. For comparison,
we used the calcium ionophore calcimycin (A23187) in
combination with the PKC activator, PMA. This treat-
ment serves as a positive control to activate NFAT in a
receptor-independent manner [23]. As shown in Figure
2, maximal induction of NFAT-dependent promoter
activity by ATP exceeded that elicited by calcimycin/
PMA. In contrast, UTP, which is an agonist of some
P2Y receptor subtypes, only marginally stimulated
reporter gene activity. The ATP derivatives a,b-meATP,
which acts as an agonist on receptors containing P2X1
or P2X3 subunits [24], and BzATP, which can activate
several P2X subtypes (P2X1-4; [24]) and human P2Y11,
had minimal effects on NFAT.
To further examine the receptors responsible for
NFAT activation in PC12 cells, we used the P2X recep-
tor antagonist PPADS (Figure 2B). Treatment of the
PC12-NFAT-Luc cells with 10 μM PPADS strongly
Figure 1 Concentration-dependent induction of NFAT-driven
reporter gene expression by extracellular ATP. PC12-NFAT-Luc
cells were treated with varying concentrations of ATP for 3 h before
lysis. Luciferase activities were normalised to the maximum
induction obtained with 300 μM ATP. The graph presents means ±
SD of n = 3 independent experiments. Nonlinear curve-fitting
yielded EC50 = 78 μM ATP (95% confidence interval 62-95 μM ATP).
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suppressed the induction of luciferase activity by ATP,
suggesting that at least one of the PPADS-sensitive P2X
subunits (P2X1, P2X2, P2X3 or P2X5; [24]) is involved
in NFAT activation.
Expression analysis of P2X receptor subunits and NFAT
isoforms in PC12 cells
The presence of the mRNA for the seven P2X receptor
subtypes was analysed by RT-PCR. As shown in Figure
3A, bands of the expected size were detected for P2X1
and P2X3-5. A more complex pattern of bands was
obtained with the P2X2-specific primers. Sequencing
revealed that the two main bands corresponded to var-
iants of P2X2 (P2X2a and P2X2b) that differ by an alter-
natively spliced region in the C-terminal domain [25].
Although P2X2 appears to be most strongly expressed
among the P2X receptors, it must be noted that bands
obtained by end-point PCR amplification of different
target sequences cannot be quantitatively compared.
Transcripts for P2X6 and P2X7 were below the detec-
tion level under our conditions (Figure 3A). Expression
of all of the 4 Ca2+-responsive NFATc isoforms was
readily shown by RT-PCR (Figure 3C).
Mechanisms of cytosolic Ca2+ increase
Activation of NFAT depends on elevated Ca2+ concen-
trations in the cytosol. Our tentative identification of a
P2X receptor raises questions about the molecular
mechanism of the Ca2+ response. Depletion of
extracellular Ca2+ prevented the induction of luciferase
activity (Figure 4A), supporting the notion that Ca2+
influx from the extracellular space is required for the
activation of NFAT by ATP. The Ca2+ needed for acti-
vation of calcineurin could enter the cell directly
through P2X cation channels and/or via voltage-gated
Ca2+ channels that open as a consequence of P2X-
mediated membrane depolarisation.
To test the latter possibility, we studied the effect of
the L-type calcium channel blocker, nifedipine, on the
induction of luciferase by ATP at the optimal concentra-
tion of ATP in this assay (300 μM) as well as a subopti-
mal concentration of 150 μM ATP (Figure 4A).
Nifedipine strongly reduced NFAT activation but did
not completely prevent the effect of ATP, indicating
that a major part of the NFAT response depends on Ca2
+ influx through L-type Ca2+ channels.
Next we asked whether store-operated Ca2+ entry
(SOCE) contributed to the effect of ATP on NFAT acti-
vation. The pyrazole derivative BTP2 is a blocker of
SOCE and inhibits NFAT effects in different cell types,
including T lymphocytes and cardiomyocytes [26,27].
Treatment with BTP2 reduced NFAT activation in
PC12 cells in a concentration-dependent manner (Figure
Figure 2 Pharmacological characterisation of purinergic
receptors that mediate NFAT activation. A, Effects of purinergic
agonists. Cells were treated with the indicated compounds at the
following final concentrations: 300 μM ATP, 300 μM UTP, 30 μM a,
b-MeATP, 30 μM BzATP or 10 μM calcimycin + 1 μM PMA. Ø,
untreated control cells. B, Effect of the P2X antagonist PPADS. PC12-
pNFAT-Luc cells were treated with ATP and PPADS as indicated
before the cells were lysed, and luciferase activity was measured.
Luciferase activities are expressed as the fold stimulation by the
treatment relative to that in cells treated with 300 μM ATP alone.
Data are shown as mean ± SD of 4 independent experiments
except for Calc+PMA (n = 3). Statistical significance is indicated for
differences vs. control (panel A) or vs. 300 μM ATP (panel B) **, p <
0.01; ***, p < 0.001.
Figure 3 Expression analysis of NFAT isoforms and P2X
receptor subunits. RT-PCR expression analysis of undifferentiated
PC12-NFAT-Luc cells with PCR primers specific for the indicated P2X
receptor (A) or NFAT isoforms (C). Panel B shows positive controls
for the P2X receptors that were not detected in undifferentiated
PC12-NFAT-Luc cells. For the amplification of P2X6, cDNA from NGF-
treated PC12-NFAT-Luc cells used as template. P2X7 was amplified
from a plasmid containing mouse P2X7 cDNA. Negative control
reactions without DNA template (control) are presented for the
primer sets for P2X6 and P2X7 (panel B) and the combined primers
sets for the 4 NFAT isoforms (panel C). Migration of size markers (M)
is indicated in bp.
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4B). Partial but significant inhibition was observed at
submicromolar concentrations (0.3 μM), at which BTP2
is thought to specifically inhibit SOCE [28,29]. A maxi-
mal effect of 72% inhibition was observed at a concen-
tration of 30 μM BTP2. It must be noted that the direct
molecular target(s) of BTP2 are still not well defined
[29], and the unsteady slope of the concentration-
response curve might suggest that there is more than
one target affected by BTP2. Taken together, these
results suggest that the maximal activation of NFAT by
extracellular ATP in PC12 cells requires the influx of
extracellular Ca2+ ions both via voltage-dependent cal-
cium channels and a BTP2-sensitive mechanism.
Pathway for the ATP activation of NFAT
We used specific inhibitors of protein phosphatase 2B/
calcineurin (FK506, also known as tacrolimus) and pro-
tein kinase MEK1 (PD98059) to examine the intracellu-
lar pathways involved in NFAT activation. FK506
suppressed ATP-induced luciferase activity, confirming
that the reporter gene expression indeed depended on
the calcineurin-NFAT pathway (Figure 5A). Interest-
ingly, the MEK inhibitor PD98059 also reduced reporter
gene activity, suggesting that activation of the MEK/
ERK1/2 cascade was required for maximal induction of
NFAT transcriptional activity. To verify that extracellu-
lar ATP can activate the MEK/ERK pathway, PC12 cells
were treated with varying concentrations of ATP, and
activation of ERK1/2 was monitored by Western blot
analysis with an activation-state specific antibody (Figure
5B). Phosphorylation of ERK1/2 was well detectable
after treatment with 37.5 μM of ATP. This response
was fully dependent on extracellular Ca2+ and was
partially inhibited by PPADS (Figure 5C), suggesting
that ERK1/2 phosphorylation required the activation of
P2X receptors.
Effect of extracellular ATP on NFAT target genes
Finally, we aimed to confirm that extracellular ATP reg-
ulates the expression of endogenous NFAT target genes
in PC12 cells. Firstly, we examined the effect of ATP on
mRNA levels of RCAN1-4 (also known as DSCR1 or
calcipressin [30]), which is a target transcript of NFAT
in various cell types, including neurons [20,31]. As
shown in Figure 6A, transcript levels of RCAN1-4 were
significantly induced by treatment with ATP, indicating
that the activation of NFAT by purinergic receptors eli-
cits transcriptional changes in PC12 cells. The upregula-
tion of RCAN1-4 mRNA depended on the activation of
the calcineurin-NFAT pathway, as confirmed by the
inhibitory effect of FK506. As a second NFAT target
transcript, we analysed the levels of the exon IV-con-
taining transcripts of the Bdnf gene. Transcripts of the
Bdnf gene can initiate with either of at least 8 different
5’-exons [32], of which the Bdnf exon IV-containing
transcripts are selectively induced by the influx of extra-
cellular calcium [33], and promoter IV is known to con-
tain a NFAT response element [34]. Similar to RCAN1-
4, we observed an increase of the Bdnf-IV transcripts in
ATP stimulated cells that was blocked by treatment
with FK506 (Figure 6B). However, these changes did not
reach the level of statistical significance.
Discussion
Our results show that the Ca2+ response elicited by
extracellular ATP in neuronal cells translates into
Figure 4 Ca2+ channel blockers inhibit ATP-induced NFAT activation. A, Effect of nifedipine and dependence on extracellular calcium. PC12-
NFAT-Luc cells were treated for 3 h with ATP and nifedipine as indicated or were stimulated with ATP in the absence of extracellular free Ca2+.
Nominal Ca2+-free conditions were created using 2 mM EGTA. Statistical significance is indicated for differences vs. the control cells treated only
with 300 μM ATP or 150 μM ATP ***, p < 0.001. B, Effect of BTP2. Cells were treated with varying concentrations of BTP2 during ATP stimulation.
A simple inhibitor-response curve was tentatively fitted to the data, although more than one mechanism may contribute to the inhibitory effect
of BTP2. The calculated IC50 is 1.5 μM (95% confidence interval 0.7-3.3 μM). Luciferase activities are expressed as the fold stimulation by the
treatment relative to that in cells only treated with 300 μM ATP. Both graphs show means ± SD of 3 independent experiments.
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changes in gene expression that are mediated by the
transcription factor NFAT. In the PC12 cells that we
used as a model system, NFAT activation by ATP
required the influx of Ca2+ from the extracellular space
and depended on the activation of P2X receptors and
the function of L-type voltage-dependent Ca2+ channels.
The calcineurin-NFAT pathway plays an important role
in neuronal development, and our results support the
assumption that purinergic receptors transmit some of
their trophic effects by this mechanism [2].
Based on the results of the present study, we propose
the following working model for the signalling events
that result in NFAT activation (Figure 7). Firstly, the
requirement of extracellular Ca2+ and the inhibitory
effect of nifedipine clearly indicate that the activation of
ionotropic P2X receptors, as opposed to the metabotro-
pic P2Y or P1 receptors, is essential for NFAT activa-
tion. Our result is in accordance with previous studies
of ATP-induced Ca2+ influx in PC12 cells [13,35], which
showed that Na+ influx through P2X2 receptors can
cause sufficient membrane depolarisation to activate L-
type voltage-gated Ca2+ channels. The fact that even 5
μM of nifedipine incompletely blocked NFAT activation
suggests that other mechanisms, such as direct Ca2+
entry through the P2X receptor pore or a BTP2-sensi-
tive channel (see below), contribute to the ATP-induced
Ca2+ response.
Figure 5 ATP-induced MEK-ERK1/2 signalling contributes to
NFAT activation. A, Effect of FK506 and PD98059 on ATP-induced
NFAT activity. Cells were treated with ATP and the inhibitors as
indicated. B and C, Activation of ERK1/2 by extracellular ATP. PC12
cells were stimulated with varying concentrations of ATP as
indicated for 10 min before cells were lysed (B). Activation of ERK1
and ERK2 was detected by Western blot analysis with antibodies
specific for the phosphorylated forms of ERK1 and ERK2 (P-ERK) and
total ERK1/2 (panERK). In C and D, cells were pretreated for 30 min
with either PPADS (10 μM), PD98059 (10 μM) or solvent (DMSO) or
were not pretreated (Ø) before stimulation with ATP, or were kept
under Ca2+-free conditions. P-ERK band intensities were quantified
and normalised to the corresponding panERK signal. The graph in
panel D presents the results of three independent experiments
(means ± SD). Treatment with Ca2+-free medium was performed
only twice, and here the mean of the two values is shown.
Statistical significance of the results in A and D is indicated for
differences vs. the control cells treated only with 300 μM ATP (*, p
< 0.05; **, p < 0.01. ***, p < 0.001).
Figure 6 Effect of ATP treatment on mRNA levels of NFAT
target genes. PC12-NFAT-Luc cells were treated with varying
concentrations of ATP as indicated and FK506 (10 nM) for 3 hours.
RCAN1-4 mRNA and exon VI-containing BDNF mRNA were
measured by real-time PCR quantification, and the results are shown
as the fold induction relative to untreated cells. The graph shows
the means ± SD of 3 independent experiments. Statistical
significance is indicated for differences of ATP-treated cells vs. the
control cells and for FK506 + 300 μM ATP-treated cells vs. cells
treated only with 300 μM ATP (*, p < 0.05; **, p < 0.01. ***, p <
0.001).
Figure 7 Model of the proposed pathway by which
extracellular ATP activates NFAT in PC12 cells. The results
demonstrate the requirement of Ca2+ influx from the extracellular
space and the contribution of both calcineurin-NFATc and MEK-
ERK1/2 pathways. The scheme also illustrates the inhibitors used for
pharmacological characterisation. BTP2 is a blocker of SOCE and
inhibits TRPC channels, but its direct molecular target in PC12 cells
is not clear.
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Secondly, the pharmacological characterisation of the
purinergic receptor responsible for NFAT activation
supports the hypothesis that a P2X receptor is critically
involved. At a concentration of 10 μM, PPADS is an
antagonist of homo- or heteromeric P2X complexes that
contain P2X1, P2X2, P2X3 or P2X5 subunits but does
not inhibit P2X4 and P2X6 [24,36]. Variable potencies
have been reported for the inhibition of P2X7 by
PPADS, with IC50 values ranging from ~100 nM to > 50
μM. However, we can exclude P2X7 here as the relevant
receptor because 30 μM BzATP failed to induce lucifer-
ase expression despite the fact that rat P2X7 is highly
responsive to BzATP in the low μM range [37]. In addi-
tion, P2X7 is a low affinity ATP receptor (EC50 > 100
μM [24]), whereas significant NFAT activation in PC12
cells was already detectable at low micromolar concen-
trations of ATP. The result that P2X7 does not account
for NFAT activation by extracellular ATP in PC12 cells
is important because P2X7 mediates NFAT activation in
other cell types such as microglia and T cells [38-42].
Finally, the lack of an effect of 30 μM a,b -MeATP
excludes the possibility that P2X1 or P2X3 induces the
activation of NFAT in PC12 cells because these recep-
tors are activated by submicromolar concentrations of
this agonist [24]. Thus, P2X2 and P2X5 remain as the
most likely candidates for activating receptors in this
pathway.
Based on our data as well as published results, we
favour the hypothesis that P2X2 is responsible for the
major part of the ATP-induced Ca2+-influx and NFAT
activation in our cell model for three reasons: i) the
P2X2 receptor was originally cloned from PC12 cells
[43] and appears to be the major P2X isoform in undif-
ferentiated PC12 cells, whereas P2X5 was either
reported to be undetectable [44] or found to be
expressed at lower levels (Figure 3A, [15,44]), ii) calcium
influx through P2X2 receptors results in the activation
of the MAP kinase cascade [45], and iii) P2X2 differs
from other P2X isoforms, including P2X5, in its slow
desensitisation kinetics [46] and is thus capable of caus-
ing sufficient depolarisation of PC12 cells to induce Ca2
+ influx via L-type voltage-gated Ca2+ channels [13,47].
The RT-PCR analysis of the PC12 clone used in the pre-
sent study confirmed that the cells express both the
slowly desensitising P2X2a isoform and the fast desensi-
tising P2X2b splicing variants (Figure 3A).
Thirdly, we showed that, in addition to the depen-
dence on calcineurin activity, maximal NFAT activation
also depended on the activation of ERK1/2 (Figure 4).
Similarly, MEK1-ERK1/2 signalling augments NFAT
transcriptional activity in cultured neonatal cardiomyo-
cytes [48,49]. As suggested by Sanna et al. [48], the
MEK1-ERK1/2 pathway and the calcineurin-NFAT path-
way may converge at the level of the transcription
factors. Importantly, Ca2+-induced calcineurin activity
alone is not always sufficient to activate NFAT-depen-
dent transcriptional activity, but a second signal that
activates the nuclear partner protein of NFAT (NFATn)
may be required (Figure 6). AP1, which is a target of
ERK1/2, is one of the nuclear partners of NFAT [50,51].
The simultaneous activation of calcineurin and the
MEK-ERK1/2 pathway may explain the very strong
ATP-induced NFAT activation that exceeds the effect
elicited by the control treatment (PMA and calcimycin).
Finally, we have shown that BTP2 partially inhibited
ATP-induced NFAT activation in PC12 cells (Figure
3B), indicating that a BTP2-sensitive Ca2+ influx is
necessary for the maximal response under the experi-
mental conditions chosen (incubation time of 3 h).
BTP2 is a selective inhibitor of capacitative Ca2+ entry
and does not affect Ca2+ handling by mitochondria or
endoplasmic reticulum or other Ca2+ channels [29].
NFAT activation in lymphocytes strictly depends on
store-operated Ca2+ entry (SOCE)[29], but there exist
conflicting data about the contribution of SOCE to Ca2+
responses in PC12 cells [35,47,52]. Unfortunately,
although several transient receptor potential (TRP)
channels have been proposed as targets of BTP2
[28,53,54], the primary target of BTP2 is still a matter of
debate, and the IC50 values obtained in different experi-
mental systems vary significantly [29]. Therefore, the
nature of the BTP2-sensitive mechanism in PC12 cells
cannot be deduced from the present experiments,
although a TRPC channel may contribute to Ca2+ influx
in PC12 cells.
We have found that extracellular ATP upregulates
RCAN1-4 mRNA, which is known to be transcribed
from an NFAT-regulated promoter [20,31]. Rcan1
encodes a negative feedback regulator of calcineurin and
has multiple effects in neurons, including regulation of
vesicle exocytosis, long-term potentiation and facilitation
of apoptosis [55-58]. However, NFAT has many more
functions in central and peripheral neurons, in particu-
lar as a transcription factor that transduces effects of
neurotrophins and membrane depolarisation
[9,10,20,59,60]. ATP is well known to change gene
expression in neurons and has multiple effects on neu-
rogenesis, neuronal differentiation and neuroprotection
[8,61-63]. Based on the results obtained in neuronal
PC12 cells as a model system, we propose that the calci-
neurin-NFAT pathway is a novel mechanism that med-
iates the trophic functions of extracellular ATP on
neurons.
Conclusions
Our analysis of ATP-induced NFAT activation in PC12
cells has identified a novel pathway through which
extracellular ATP can regulate neuronal gene expression
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and thereby modulate the function and development of
neurons. In contrast to immune cells and glia, where
P2X7 mediates activation of NFAT, available evidence
suggests that, in neurons, P2X2 accounts for this effect.
P2X2 produces depolarisation-induced calcium influx
through L-type Ca2+ channels and the activation of
MEK-ERK1/2 signalling, which are both required for
maximal NFAT activation. We propose this pathway as
a more general mechanism by which extracellular ATP
can exert long-term effects on neuronal cells, which
remains to be studied under physiological conditions.
Methods
Reagents
ATP, UTP, 3’-O-(4-benzoyl)benzoyl ATP (BzATP), nife-
dipine, a,b-MeATP (a,b-methylene-ATP) and PD98059
were obtained from Sigma (Taufkirchen, Germany).
Phorbol 12-myristate 13-acetate (PMA), calcimycin (also
known as A23187) and FK506 (Tacrolimus) were pur-
chased from Calbiochem (San Diego, CA). Pyridoxal-
phosphate-6-azophenyl-2’,4’-disulfonate (PPADS) was
obtained from Biotrend (Cologne, Germany) and BTP2
(a 3,5-bis(trifluoromethyl)pyrazole derivative, also called
YM-58483) was obtained from Cayman Chemical (Ann
Arbor, MI). Stock solutions of nifedipine, BTP2, FK506,
PD98059 and PMA were prepared in DMSO. ATP, UTP
and PPADS were dissolved in water, and calcimycin was
dissolved in ethanol.
Cell culture conditions
PC12 cells were grown in high glucose (4.5 g/L) Dulbec-
co’s modified Eagles medium (DMEM) with L-glutamine
and sodium pyruvate, supplemented with 5% foetal
bovine serum (PAA Laboratories, Pasching, Austria),
10% horse serum (PAA) and 25 mM Hepes buffer
(Sigma). Cells were grown to 60-80% confluency in 5%
CO2 at 37°C in T75 filter flasks, and cultures were split
every 48-72 h without trypsinisation. When indicated,
nominal Ca2+ -free conditions were created by adding
EGTA to a final concentration of 2 mM. To assess cell
viability after ATP treatment, the percentage of stained
cells in the trypan blue uptake assay was calculated
from hemacytometer counts of at least 300 cells per
sample.
Construction of PC12-NFAT-Luc cells
A PC12 subclone with a stably integrated NFAT-depen-
dent luciferase reporter vector was generated in two
steps. First, a Flp recombination target (FRT) site was
integrated in the genome by transfecting PC12 cells
with pFRT/LacZeo (Invitrogen, Carlsbad, CA) and
selecting clones resistant to 100 μg/ml Zeocin. Second,
the hygromycin resistance gene with a FRT site
embedded in the 5’ coding region was transferred from
pcDNA5/FRT/TO (Invitrogen) into pNFAT-Luc (Strata-
gene, La Jolla, CA) to generate pNFAT-Luc/FRT. This
plasmid was then integrated into the FRT-containing
PC12 clone via Flp recombinase-mediated DNA recom-
bination according to the manufacturer’s instructions.
Luciferase expression from pNFAT-Luc is under the
control of four direct repeats of the NFAT binding
sequence (GGAGGAAAAACTGTTTCATACA-
GAAGGCGT) from the IL-2 gene promoter.
Reporter gene assays
For the luciferase assays, PC12-NFAT-Luc cells were
plated at 40,000 cells/100 μl/well in a 96-well plate. The
following day, the culture medium was completely
removed and replaced with medium containing the
agents to be tested in the experiment. Antagonists or
inhibitors were applied 30 min before stimulation with
ATP. After 3 h of incubation, the medium was removed,
and the cells were lysed in passive lysis buffer (Promega,
Madison, WI) by vigorous shaking for 1 min at room
temperature. Luciferase activity was determined by mix-
ing an aliquot of the lysate with 4 vol of the luciferase
assay mix according to Gaunitz and Papke [64] and
measuring light emission in an Orion Microplate
Luminometer (Berthold Detection Systems, Pforzheim,
Germany). All data were obtained from triplicate wells.
Western blotting
Whole cell lysates for immunodetection of ERK phos-
phorylation were prepared by collecting the cells by cen-
trifugation in a micro test tube and subsequent lysis
with 100 μl/well (in a 6-well plate) boiling SDS-buffer
(20 mM Tris, pH 7.4; 1% SDS). The phosphorylation of
ERK1/2 was assessed by Western blot analysis using
polyclonal rabbit antibodies specific for phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) and total p44/42
MAPK (Cell Signaling Technology, Danvers, MA). The
Western blots were developed using horseradish peroxi-
dase-coupled secondary antibodies and chemilumines-
cence detection. Signal intensities were quantitated with
a LAS-3000 CCD imaging system and the AIDA Image
Analyzer 5.0 program (Raytest, Straubenhardt,
Germany).
Quantitative RT-PCR
To quantify the mRNA levels of RCAN1 and BDNF,
3x106 PC12-NFAT-Luc cells were plated in 60 mm cul-
ture dishes. The next day, the medium was changed,
and ATP and FK506 were added. The cells were incu-
bated with ATP for 3 h, while FK506 was added 30 min
before stimulation with ATP. The RNeasy Mini Kit
(Qiagen, Hilden, Germany) was used for RNA purifica-
tion according to the manual. For the cDNA synthesis,
1 μg of total RNA was reverse transcribed using 1 μg of
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oligo(dT) and MMLV reverse transcriptase (Promega) at
40°C for 1 h. The resulting cDNAs were analysed using
a LightCycler 480 system and SYBR Green master mix
reagent (Roche Applied Science), using the following
PCR conditions: 5 min initial denaturation at 95°C, fol-
lowed by 45 cycles of 10 s at 95°C, 10 s at 50-62°C, 15 s
at 72°C and 1 s at 74°C. The sequences of the oligonu-
cleotide primers used for the specific detection of the
rat RCAN1-4 transcript [GenBank NM_153724.2] and
the exon IV-containing Bdnf transcript [GenBank
EF125679.1] are given in the Supplementary material
(Additional file 1). The beta-2 microglobulin gene was
used as a housekeeping gene for normalization.
Endpoint RT-PCR
The sequences of the primers used for the amplification
of the P2X and NFAT sequences are given in the Sup-
plementary material (additional file 1). The REDTaq
PCR Reaction Mix (Sigma) was used under the following
PCR conditions: 2 min initial denaturation at 94°C, fol-
lowed by 35 cycles of 30 s at 94°C, 30 s at 52-58°C and
1 min at 72°C. The positive control plasmid for amplifi-
cation of P2X7 cDNA was kindly provided by Günther
Schmalzing in our Institute.
Statistical analysis
The GraphPad Prism 5.0 program (GraphPad Software,
La Jolla, CA) was used for curve fitting by nonlinear
regression and statistical analysis. Results were tested for
statistical significance by ANOVA and Bonferroni’s cor-
rection for multiple comparisons.
Additional material
Additional file 1: Primer sequences. This PDF file lists the
oligonucleotide sequences of the PCR primers used in this study.
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